United Kingdom Bronchodilators Market By Type (Beta-Adrenergic Bronchodilators, Anticholinergic Bronchodilators, Xanthine Derivatives, and Others), By Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others), By Route of Administration (Oral, Nasal, and Injectable), By Region, Competition, Forecast and Opportunities, 2028
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationUnited Kingdom Bronchodilators Market By Type (Beta-Adrenergic Bronchodilators, Anticholinergic Bronchodilators, Xanthine Derivatives, and Others), By Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others), By Route of Administration (Oral, Nasal, and Injectable), By Region, Competition, Forecast and Opportunities, 2028
Acute (sudden) asthma symptoms are quickly relieved or eliminated by short-acting bronchodilators. They last between 3-6. A rescue inhaler is another term for a short-acting bronchodilator.
Bronchodilators are often administered through various inhalation devices such as metered-dose inhalers, dry powder inhalers, and nebulizers. The increased demand for bronchodilators correlates with a higher demand for these medical devices, as patients require appropriate inhalation devices for effective drug delivery. The primary function of bronchodilators is to relax the smooth muscles lining the airways (bronchi and bronchioles). By stimulating the beta-2 adrenergic receptors in the smooth muscles, bronchodilators cause the muscles to relax, resulting in the dilation or widening of the airways. This allows for improved airflow and easier breathing. These factors may anticipate in the growth of United Kingdom Bronchodilators Market.
Increasing Smoking Rates May Drives the Market
In the UK, 6.6 million people or 13.3% of adults (18 years and older) smoked cigarettes in 2021. around .
Increasing Incidence of Chronic Obstructive Pulmonary Disease (COPD)
After asthma, COPD is the second most prevalent lung disease in the UK. 4.5% of all adults over 40 and 2% of the general population, respectively, have Chronic Obstructive Pulmonary Disease (COPD).
Bronchodilators are crucial for managing Chronic Obstructive Pulmonary Disease (COPD) symptoms such as breathlessness, coughing, and wheezing. They help to improve airflow and relieve bronchial constriction. Additionally, bronchodilators play a role in preventing exacerbations, which can be severe and require medical intervention. The need for symptom management and exacerbation prevention drives the growth of Bronchodilators Market in United Kingdom. The National Health Service (NHS) in the United Kingdom provides guidelines for the management of COPD, emphasizing the use of bronchodilators as a key component of treatment. The guidelines recommend the use of short-acting bronchodilators as rescue medication and long-acting bronchodilators as maintenance therapy. The NHS has developed integrated care pathways for COPD, which provide guidance on the management of COPD across different healthcare settings. The adherence to these guidelines drives the demand for bronchodilators in the market.
Increase In Ageing Population
4.5% of people aged 40+ having COPD & similarly, around 7.8% of older adults in United Kingdom have Asthma.
Recent Development
- In 2020, Astrazenca acquire Alexion pharmaceuticals in USD60 Million in cash and 2.1243 AstraZeneca American Depositary shares (ADSs) To encourage future medical innovation, the combined companies will bring together two patient-centric models of care delivery that are quickly convergent and have complementary capabilities in immunology, biologics, genomics, and oligonucleotides.
- In 2023, AstraZeneca acquire Cincor’s a transaction value of approximately $1.8bn and a 206% premium over CinCor’s closing market price on 6 January 2023 attentive on developing novel treatments for unaffected and uncontrolled hypertension as well as chronic kidney disease.
- In 2020, Novartis AG acquire The Medicine Company the company to be received USD 85.00 per share to begin a new chapter on the use of a vaccine-like strategy for treating the biggest cause of death and disability in the world. It represents a huge advancement in our efforts to refocus the business, rethink medicine, and alter the course of human history.
Download Free Sample Report
Market Segmentation
The United Kingdom Bronchodilators Market can be segmented by Type, Indication, Route of Administration, End User, and region. Based on Type, the market can be segmented into Beta-Adrenergic Bronchodilators, Anticholinergic Bronchodilators, Xanthine Derivatives, and Others. Based on Indication, the market can be grouped into Asthma, Chronic Obstructive Pulmonary Disease (COPD), Others. Based on Route of Administration, the market can be segmented into Oral, Nasal, Injectable.
Market Players
AstraZeneca PLC, Boehringer Ingelheim GmbH, Novartis AG, Teva Pharmaceutical Industries Ltd., Cipla EU Ltd, Sunovion Pharmaceuticals Ltd, GlaxoSmithKline Inc/United Kingdom. are some of the leading players operating in the United Kingdom bronchodilators market.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
| Report Coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments Covered | Type Indication Route of Administration End User |
| Regional scope | Scotland, South-East, London, South-West, Yorkshire & Humberside, and East Midlands |
| Key companies profiled | AstraZeneca PLC, Boehringer Ingelheim GmbH, Novartis AG, Teva Pharmaceutical Industries Ltd., Cipla EU Ltd, Sunovion Pharmaceuticals Ltd, GlaxoSmithKline Inc/United Kingdom. |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Report Scope
In this report, the United Kingdom bronchodilators market has been segmented into the following categories, in addition to the industry trends which have also been detailed below
- United Kingdom Bronchodilators Market, By Type
o
o
o
o
- United Kingdom Bronchodilators Market, By Indication
o
o
o
o
o
- United Kingdom Bronchodilators Market, By Route of Administration
o
o
o
- United Kingdom Bronchodilators Market, By Region
o
o
o
o
o
o
Competitive Landscape
Company Profiles
found at Customizations
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are found at for the report
Company Information
- Detailed analysis and profiling of additional market players (up to five).
The United Kingdom bronchodilators market has an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy